Free Trial

Cytek Biosciences Q3 2024 Earnings Report

Cytek Biosciences logo
$6.70 -0.22 (-3.18%)
(As of 12/3/2024 05:16 PM ET)

Cytek Biosciences EPS Results

Actual EPS
$0.01
Consensus EPS
-$0.02
Beat/Miss
Beat by +$0.03
One Year Ago EPS
-$0.03

Cytek Biosciences Revenue Results

Actual Revenue
$51.50 million
Expected Revenue
$50.63 million
Beat/Miss
Beat by +$870.00 thousand
YoY Revenue Growth
N/A

Cytek Biosciences Announcement Details

Quarter
Q3 2024
Time
After Market Closes
One coin could soar when Trump’s elected … (Ad)

Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”

Click here to find out more about what could be Trump and JD Vance’s favorite coin.

Cytek Biosciences Earnings Headlines

Piper Sandler Sticks to Its Buy Rating for Cytek Biosciences (CTKB)
One coin could soar when Trump’s elected …
Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”
Cautious Hold on Cytek Biosciences Amid Recovery and Growth Opportunities
Cytek Biosciences price target raised to $8.50 from $8 at Piper Sandler
See More Cytek Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cytek Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cytek Biosciences and other key companies, straight to your email.

About Cytek Biosciences

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

View Cytek Biosciences Profile

More Earnings Resources from MarketBeat